Cargando…
Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD
BACKGROUND: Formoterol fumarate inhalation solution (FFIS; Perforomist(®)) is a long-acting β(2)-agonist (LABA) marketed in the US as a nebulized COPD maintenance treatment. Because long-term LABA use was associated with a potential increased risk of exacerbation or death in asthma patients, the US...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311322/ https://www.ncbi.nlm.nih.gov/pubmed/30643398 http://dx.doi.org/10.2147/COPD.S173595 |